{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:28:40Z","timestamp":1788355720539,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008238","name":"Hebei Provincial Department of Bureau of Science and Technology","doi-asserted-by":"publisher","award":["183977118D"],"award-info":[{"award-number":["183977118D"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014882","name":"Department of Finance of Hebei","doi-asserted-by":"publisher","award":["361004"],"award-info":[{"award-number":["361004"]}],"id":[{"id":"10.13039\/501100014882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>As a marker of inflammation, calprotectin has potential application value in a variety of inflammatory diseases, such as arthritis and bacterial infections. <jats:italic>Clostridioides difficile<\/jats:italic> infection (CDI) is an infectious disease that causes intestinal damage and inflammation. This systematic review aims to determine whether fecal calprotectin has application value in CDI. Nine databases were searched from inception to 6 June 2022, and 17 studies were included. These studies were divided into four groups according to their content. Generally speaking, fecal calprotectin is not an ideal indicator for the diagnosis and prognosis prediction of CDI but may serve as a potential indicator for assessing disease severity and as a readily detectable marker for CDI screening. In addition, patients in need of treatment or with detectable toxins in stool may tend to have higher levels of fecal calprotectin. In summary, fecal calprotectin has some potential application value in CDI. However, further studies are needed to verify these findings and determine the reliability of calprotectin as a biomarker for CDI.<\/jats:p>","DOI":"10.3389\/fphys.2022.881816","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T05:07:48Z","timestamp":1659503268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The value of fecal calprotectin in Clostridioides difficile infection: A systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Bao-Jiang","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ger","family":"Te","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.15171\/mejdd.2018.123","article-title":"Clinical and pathological features of ulcerative colitis in patients with and without clostridium difficile infection; an observational study","volume":"11","author":"Aletaha","year":"2019","journal-title":"Middle East J. Dig. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/00365521.2017.1392598","article-title":"Fecal calprotectin in management of Clostridium difficile infection: A longitudinal study","volume":"53","author":"Antonella","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1111\/jgh.15072","article-title":"Fecal calprotectin and need of multiple microbiota trasplantation infusions in Clostridium difficile infection","volume":"35","author":"Antonella","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s10096-017-3080-y","article-title":"Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: A case-control study","volume":"36","author":"Barbut","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.diagmicrobio.2018.10.006","article-title":"Calprotectin and calgranulin C serum levels in bacterial sepsis","volume":"93","author":"Bart\u00e1kov\u00e1","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jinf.2007.09.015","article-title":"Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system","volume":"55","author":"Belmares","year":"2007","journal-title":"J. Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","article-title":"European society of clinical Microbiology and infectious diseases: Update of the diagnostic guidance document for Clostridium difficile infection","volume":"22","author":"Crobach","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European society of clinical Microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"B10","doi-asserted-by":"publisher","first-page":"147973","DOI":"10.1155\/2015\/147973","article-title":"Serum calprotectin: A potential biomarker for neonatal sepsis","volume":"2015","author":"Decembrino","year":"2015","journal-title":"J. Immunol. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1086\/658336","article-title":"Comparison of clinical severity score indices for Clostridium difficile infection","volume":"32","author":"Fujitani","year":"2011","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in u.s. Burden of clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10067-015-3108-6","article-title":"Serum calprotectin--a promising diagnostic marker for adult-onset Still's disease","volume":"35","author":"Guo","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E882","DOI":"10.3390\/microorganisms8060882","article-title":"Investigation of intestinal microbiota and fecal calprotectin in Non-Toxigenic and toxigenic clostridioides difficile colonization and infection","volume":"8","author":"Han","year":"2020","journal-title":"Microorganisms"},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/ipc.0000000000000312","article-title":"Fecal calprotectin in the diagnosis of Clostridium difficile infection","volume":"24","author":"Hanania","year":"2016","journal-title":"Infect. Dis. Clin. Pract. Balt. Md."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1039\/d1an00726b","article-title":"Rapid ultra-sensitive diagnosis of clostridium difficile infection using a SERS-based lateral flow assay","volume":"146","author":"Hassanain","year":"2021","journal-title":"Analyst"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.anaerobe.2019.03.006","article-title":"Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection","volume":"56","author":"Hibbard","year":"2019","journal-title":"Anaerobe"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e218721","DOI":"10.1128\/jcm.02187-21","article-title":"Clinical outcomes of treated and untreated C. difficile PCR-positive\/toxin-negative adult hospitalized patients: A quasi-experimental noninferiority study","volume":"60","author":"Hogan","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3343\/alm.2017.37.1.53","article-title":"Fecal calprotectin level reflects the severity of Clostridium difficile infection","volume":"37","author":"Jieun","year":"2017","journal-title":"Ann. Lab. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/2277-9175.156647","article-title":"Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome","volume":"4","author":"Kalantari","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/ajg.2016.342","article-title":"Serum calprotectin: A novel diagnostic and prognostic marker in inflammatory bowel diseases","volume":"111","author":"Kalla","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/cid\/ciz330","article-title":"Host immune markers distinguish clostridioides difficile infection from asymptomatic carriage and non-C. Difficile diarrhea","volume":"70","author":"Kelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1017\/ice.2016.210","article-title":"Inappropriate clostridium difficile testing and consequent overtreatment and inaccurate publicly reported metrics","volume":"37","author":"Kelly","year":"2016","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cca.2020.08.025","article-title":"Calprotectin in inflammatory bowel disease","volume":"510","author":"Khaki-Khatibi","year":"2020","journal-title":"Clin. Chim. Acta."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.mayocp.2012.07.016","article-title":"Clostridium difficile infection: New insights into management","volume":"87","author":"Khanna","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/01.MIB.0000442681.85545.31","article-title":"Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease","volume":"20","author":"Kopylov","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40121-021-00417-7","article-title":"Clostridium difficile: Diagnosis and the consequence of over diagnosis","volume":"10","author":"Lee","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/jamainternmed.2016.0177","article-title":"Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C difficile infections: A quasi-experimental controlled study","volume":"176","author":"Longtin","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-018-4980-0","article-title":"Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis","volume":"63","author":"Mak","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cmi.2019.02.002","article-title":"Universal screening for Clostridioides difficile in a tertiary hospital: Risk factors for carriage and clinical disease","volume":"25","author":"Meltzer","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2334-13-148","article-title":"Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy","volume":"13","author":"Miller","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"B33","first-page":"53","article-title":"The level of fecal calprotectin significantly correlates with Clostridium difficile infection severity","volume":"59","author":"Miros\u0142aw","year":"2019","journal-title":"Folia Med. cracov."},{"key":"B34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.22088\/cjim.8.3.178","article-title":"Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic","volume":"8","author":"Moein","year":"2017","journal-title":"Casp. J. Intern. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"M278","DOI":"10.1136\/mp.48.5.m278","article-title":"Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein)","volume":"48","author":"Naess-Andresen","year":"1995","journal-title":"Clin. Mol. Pathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/INF.0000000000001450","article-title":"Recurrent clostridium difficile infection in children: Patient risk factors and markers of intestinal inflammation","volume":"36","author":"Nicholson","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12879-016-1618-8","article-title":"Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection","volume":"16","author":"Peretz","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/23744235.2016.1186832","article-title":"Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults","volume":"48","author":"Rao","year":"2016","journal-title":"Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/2050640618784046","article-title":"Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice","volume":"6","author":"Reenaers","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.amjmed.2008.06.034","article-title":"Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea","volume":"121","author":"Shastri","year":"2008","journal-title":"Am. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3390\/jcm10081627","article-title":"Usefulness of fecal calprotectin in the management of patients with toxigenic clostridioides difficile","volume":"10","author":"Suarez-Caranto\u00f1a","year":"2021","journal-title":"J. Clin. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e106118","DOI":"10.1371\/journal.pone.0106118","article-title":"Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): A prospective cohort study","volume":"9","author":"Swale","year":"2017","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s10096-018-3381-9","article-title":"Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection","volume":"37","author":"He","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults","volume":"27","author":"Van Prehn","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.12865\/CHSJ.47.02.09","article-title":"Clostridoides difficile infection severity assessment by fecal calprotectin: A pilot study","volume":"47","author":"Voicu","year":"2021","journal-title":"Curr. Health Sci. J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1099\/jmm.0.067389-0","article-title":"Is there any value in measuring faecal calprotectin in Clostridium difficile positive faecal samples?","volume":"63","author":"Whitehead","year":"2014","journal-title":"J. Med. Microbiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/ajg.2015.22","article-title":"Colonization with toxinogenic C. Difficile upon hospital admission, and risk of infection: A systematic review and meta-analysis","volume":"110","author":"Zacharioudakis","year":"2015","journal-title":"Am. J. Gastroenterol."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.881816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T05:07:54Z","timestamp":1659503274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.881816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":49,"alternative-id":["10.3389\/fphys.2022.881816"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.881816","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"article-number":"881816"}}